Leronlimab takes viral load to zero in 14 days per Dr Patterson and it’s not a secondary endpoint in m2m. Is it in s2c? Will that still be given to FDA and put in our press release though? That’s something that laypeople (investors) would understand and it would be impressive to the FDA. It should be included regardless. IMO